Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Supplementary Figure 3A

Synthetic reference peptide

Original peptide

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Supplementary Figure 3B

Synthetic reference peptide

Original peptide

Supplementary Figure 3C

Synthetic reference peptide

Original peptide

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

**Supplementary Figure 3D**

Synthetic reference peptide

Original peptide

Supplementary Figure 3E

Synthetic reference peptide

Original peptide

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

Supplementary Figure 3F

Synthetic reference peptide

Original peptide

Supplementary Figure 3

Supplementary Figure 3A-F: Fragment ion spectra of cryptic HLA-I peptides identified from AT/RT samples in comparison to reference spectra generated from the corresponding synthetic peptides. HLA peptides from AT/RT samples were analyzed on an Orbitrap XL applying collisional-induced dissociation (CID) in the ion trap. Reference spectra were analyzed on an Orbitrap Velos Pro applying ion trap CID. On both instruments fragment ion spectra were recorded with the ion trap.